Defining the optimal sequence for the systemic treatment of metastatic breast cancer.

Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting a systemic treatment, it is important to consider the medication administered i...

Descripción completa

Detalles Bibliográficos
Autores: Albanell Mestres, Joan, iMolins, A. B., Martínez, L. C., López-Muñiiz, J. I. C., Gil, E. C., Juan Ferré, A. de, Barco Berrón, Sonia del, Pérez, Y. F., Mata, J. G., Palomo, A. G., Gregori, J. G., Pardo, P. G., Mañas, J. J. I., Hernández, A. L., Dueñas-Espín, Iván, 1979-, Jáñez, N. M., Murillo, S. M., Bofill, Javier Salvador, Auñón, Pilar Zamora, Sánchez-Rovira, Pedro
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/28015
Acceso en línea:http://hdl.handle.net/10230/28015
http://dx.doi.org/10.1007/s12094-016-1520-2
Access Level:acceso abierto
Palabra clave:Mama -- Càncer -- Quimioteràpia
Quimioteràpia
Metàstasi
id ES_9d934c8e30e70eeb45a1baf9cdff6903
oai_identifier_str oai:repositori.upf.edu:10230/28015
network_acronym_str ES
network_name_str España
repository_id_str
spelling Defining the optimal sequence for the systemic treatment of metastatic breast cancer.Albanell Mestres, JoaniMolins, A. B.Martínez, L. C.López-Muñiiz, J. I. C.Gil, E. C.Juan Ferré, A. deBarco Berrón, Sonia delPérez, Y. F.Mata, J. G.Palomo, A. G.Gregori, J. G.Pardo, P. G.Mañas, J. J. I.Hernández, A. L.Dueñas-Espín, Iván, 1979-Jáñez, N. M.Murillo, S. M.Bofill, Javier SalvadorAuñón, Pilar ZamoraSánchez-Rovira, PedroMama -- Càncer -- QuimioteràpiaQuimioteràpiaMetàstasiMetastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting a systemic treatment, it is important to consider the medication administered in the previous stages, such as acquired resistance, type of progression, time to relapse, tumor aggressiveness, age, comorbidities, pre- and post-menopausal status, and patient preferences. Moreover, tumor genomic signatures can identify different subtypes, which can be used to create patient profiles and design specific therapies. However, there is no consensus regarding the best treatment sequence for each subgroup of patients. During the SABCC Congress of 2014, specialized breast cancer oncologists from referral hospitals in Europe met to define patient profiles and to determine specific treatment sequences for each one. Conclusions were then debated in a final meeting in which a relative degree of consensus for each treatment sequence was established. Four patient profiles were defined according to established breast cancer phenotypes: pre-menopausal patients with luminal subtype, post-menopausal patients with luminal subtype, patients with triple-negative subtype, and patients with HER2-positive subtype. A treatment sequence was then defined, consisting of hormonal therapy with tamoxifen, aromatase inhibitors, fulvestrant, and mTOR inhibitors for pre- and post-menopausal patien ts; a chemotherapy sequence for the first, second, and further lines for luminal and triple-negative patients; and an optimal sequence for treatment with new antiHER2 therapies. Finally, a document detailing all treatment sequences, that had the agreement of all the oncologists, was drawn up as a guideline and advocacy tool for professionals treating patients with this disease.Springer20172017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/28015http://dx.doi.org/10.1007/s12094-016-1520-2reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésClinical and Translational Oncology. 2017 Feb;19(2):149-61This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/280152026-06-12T07:21:37Z
dc.title.none.fl_str_mv Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
title Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
spellingShingle Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
Albanell Mestres, Joan
Mama -- Càncer -- Quimioteràpia
Quimioteràpia
Metàstasi
title_short Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
title_full Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
title_fullStr Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
title_full_unstemmed Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
title_sort Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
dc.creator.none.fl_str_mv Albanell Mestres, Joan
iMolins, A. B.
Martínez, L. C.
López-Muñiiz, J. I. C.
Gil, E. C.
Juan Ferré, A. de
Barco Berrón, Sonia del
Pérez, Y. F.
Mata, J. G.
Palomo, A. G.
Gregori, J. G.
Pardo, P. G.
Mañas, J. J. I.
Hernández, A. L.
Dueñas-Espín, Iván, 1979-
Jáñez, N. M.
Murillo, S. M.
Bofill, Javier Salvador
Auñón, Pilar Zamora
Sánchez-Rovira, Pedro
author Albanell Mestres, Joan
author_facet Albanell Mestres, Joan
iMolins, A. B.
Martínez, L. C.
López-Muñiiz, J. I. C.
Gil, E. C.
Juan Ferré, A. de
Barco Berrón, Sonia del
Pérez, Y. F.
Mata, J. G.
Palomo, A. G.
Gregori, J. G.
Pardo, P. G.
Mañas, J. J. I.
Hernández, A. L.
Dueñas-Espín, Iván, 1979-
Jáñez, N. M.
Murillo, S. M.
Bofill, Javier Salvador
Auñón, Pilar Zamora
Sánchez-Rovira, Pedro
author_role author
author2 iMolins, A. B.
Martínez, L. C.
López-Muñiiz, J. I. C.
Gil, E. C.
Juan Ferré, A. de
Barco Berrón, Sonia del
Pérez, Y. F.
Mata, J. G.
Palomo, A. G.
Gregori, J. G.
Pardo, P. G.
Mañas, J. J. I.
Hernández, A. L.
Dueñas-Espín, Iván, 1979-
Jáñez, N. M.
Murillo, S. M.
Bofill, Javier Salvador
Auñón, Pilar Zamora
Sánchez-Rovira, Pedro
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Mama -- Càncer -- Quimioteràpia
Quimioteràpia
Metàstasi
topic Mama -- Càncer -- Quimioteràpia
Quimioteràpia
Metàstasi
description Metastatic breast cancer is a heterogeneous disease that presents in varying forms, and a growing number of therapeutic options makes it difficult to determine the best choice in each particular situation. When selecting a systemic treatment, it is important to consider the medication administered in the previous stages, such as acquired resistance, type of progression, time to relapse, tumor aggressiveness, age, comorbidities, pre- and post-menopausal status, and patient preferences. Moreover, tumor genomic signatures can identify different subtypes, which can be used to create patient profiles and design specific therapies. However, there is no consensus regarding the best treatment sequence for each subgroup of patients. During the SABCC Congress of 2014, specialized breast cancer oncologists from referral hospitals in Europe met to define patient profiles and to determine specific treatment sequences for each one. Conclusions were then debated in a final meeting in which a relative degree of consensus for each treatment sequence was established. Four patient profiles were defined according to established breast cancer phenotypes: pre-menopausal patients with luminal subtype, post-menopausal patients with luminal subtype, patients with triple-negative subtype, and patients with HER2-positive subtype. A treatment sequence was then defined, consisting of hormonal therapy with tamoxifen, aromatase inhibitors, fulvestrant, and mTOR inhibitors for pre- and post-menopausal patien ts; a chemotherapy sequence for the first, second, and further lines for luminal and triple-negative patients; and an optimal sequence for treatment with new antiHER2 therapies. Finally, a document detailing all treatment sequences, that had the agreement of all the oncologists, was drawn up as a guideline and advocacy tool for professionals treating patients with this disease.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/28015
http://dx.doi.org/10.1007/s12094-016-1520-2
url http://hdl.handle.net/10230/28015
http://dx.doi.org/10.1007/s12094-016-1520-2
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical and Translational Oncology. 2017 Feb;19(2):149-61
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869414754061123584
score 15.812455

Similares en LA Referencia